The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

Tereshchenko N.M.

Pavlov First St. Petersburg State Medical University

Gotovchikov A.A.

Pavlov First Saint Petersburg State Medical University

Clinical experience with the use of a fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndrome

Authors:

Amelin A.V., Tereshchenko N.M., Gotovchikov A.A.

More about the authors

Read: 1654 times


To cite this article:

Amelin AV, Tereshchenko NM, Gotovchikov AA. Clinical experience with the use of a fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):83‑86. (In Russ.)
https://doi.org/10.17116/jnevro202112108183

Recommended articles:

References:

  1. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):493-505.  https://doi.org/10.7326/M16-2459
  2. Cohen SP. Epidemiology, diagnosis, and treatment of neck pain. Mayo Clin Proc. 2015;90(2):284-299.  https://doi.org/10.1016/j.mayocp.2014.09.008
  3. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365-370. 
  4. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-175.  https://doi.org/10.1016/j.jpainsymman.2004.05.002
  5. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;2003(2):CD004252.
  6. Schaffler K, Reitmeir P, Gschanes A, Eggenreich U. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin. Drugs R D. 2005;6(4):189-199.  https://doi.org/10.2165/00126839-200506040-00001
  7. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy [published correction appears in Drugs 1988;36(1):preceding 1]. Drugs. 1988;35(3):244-285.  https://doi.org/10.2165/00003495-198835030-00004
  8. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26(7):1715-1731. https://doi.org/10.1185/03007995.2010.486301
  9. Kornhuber J, Parsons CG, Hartmann S, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-246.  https://doi.org/10.1007/BF01281158
  10. Pubill D, Verdaguer E, Canudas AM, et al. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol. 2001;132(3):693-702.  https://doi.org/10.1038/sj.bjp.0703869
  11. Desaphy JF, Dipalma A, De Bellis M, et al. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009;142(3):225-235.  https://doi.org/10.1016/j.pain.2009.01.010
  12. Diaconu CC, Dediu GN, Iancu MA. Drug-induced arterial hypertension — a frequently ignored cause of secondary hypertension: a review [published online ahead of print, 2018 Jan 1]. Acta Cardiol. 2018;1-7.  https://doi.org/10.1080/00015385.2017.1421445
  13. Ushkalova EA, Zyryanov SK, Zatolochina KE. The fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndromes. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):100-104. (In Russ.). https://doi.org/10.14412/2074-2711-2020-100-104
  14. Amelin AV. A fixed combination of orphenadrine and diclofenac, as possibilities of multimodal therapy of pain and muscle spasm. Russian Journal of Pain. 2019;17(4):50-53. (In Russ.). https://doi.org/10.25731/RASP.2019.04.41

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.